Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013121 | 0.83 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL23982534 | 0.83 | MEN1 (0.31) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3712259 | 0.80 | MEN1 (0.46) | MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL2943006 | 0.80 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL31319696 | 0.78 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL1012600 | 0.78 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL11291871 | 0.75 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL2677760 | 0.75 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL769538 | 0.75 | EGFR (0.33) | MEN1KMT2A | |
| SCHEMBL17732311 | 0.75 | HSD17B10 (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | MEN1 1373/4885KMT2A 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.